PMDS

Die prämenstruelle dysphorische Störung (PMDS) ist eine ernstzunehmende, medizinisch anerkannte Form zyklusabhängiger Beschwerden, die sich deutlich vom klassischen prämenstruellen Syndrom (PMS) unterscheidet. Während PMS in der Regel mit körperlichen und emotionalen Symptomen einhergeht, verursacht PMDS schwerwiegende psychische Beeinträchtigungen wie Depression, Wutausbrüche, Kontrollverlust und Suizidgedanken. Die Beschwerden treten regelmäßig in der Lutealphase – also nach dem Eisprung – auf und verschwinden typischerweise mit Beginn der Menstruation. PMDS betrifft schätzungsweise 3 bis 8 % der menstruierenden Frauen, wird jedoch häufig nicht erkannt oder falsch diagnostiziert. Der Artikel erklärt fundiert die neurobiologischen Ursachen, das Zusammenspiel von Hormonverarbeitung und Gehirn, die typischen Symptome sowie wirksame Behandlungsoptionen – von Hormontherapie über Antidepressiva bis hin zu pflanzlichen Mitteln wie Mönchspfeffer und CBD-Zäpfchen. Ziel ist es, Betroffene zu informieren, medizinisches Fachwissen bereitzustellen und Wege aufzuzeigen, wie Lebensqualität trotz PMDS zurückgewonnen werden kann.
Philip Schmiedhofer, MSc

Autor

Philip Schmiedhofer, MSc

Inhaltsverzeichnis

What is PMDS and how is it different from PMS?

Premenstrual dysphoric disorder (PMDD) – internationally also known as Premenstrual Dysphoric Disorder (PMDD) – is a severe, neurobiologically based cycle disorder that causes psychological and partly physical symptoms.

How common is premenstrual dysphoric disorder?

Premenstrual dysphoric disorder (PMDD) is a significantly less commonly diagnosed but clinically important form of cycle-dependent complaints.

What causes PMDS?

Premenstrual dysphoric disorder (PMDD) is not imaginary, not a character weakness, and not purely a psychological reaction to stress.

What role does the cycle play in PMDS?

The phases of the menstrual cycle are the central trigger for the symptoms of premenstrual dysphoric disorder (PMDD).

What symptoms are typical for PMDS?

Premenstrual dysphoric disorder (PMDD) is characterized by a variety of severe, cycle-dependent symptoms – primarily psychological in nature, but also with physical accompanying symptoms.

How is PMDS diagnosed?

The diagnosis of premenstrual dysphoric disorder (PMDD) requires care, patience, and systematic observation.

How does PMDS progress over the years?

Premenstrual dysphoric disorder (PMDD) shows a highly variable individual course, closely linked to hormonal changes, life phases, and psychosocial stressors.

What treatment options are available for PMDS?

The treatment of premenstrual dysphoric disorder (PMDD) requires an individually tailored, multimodal therapy concept that takes into account both the neurobiological cause and the psychosocial stress factors.

Does the pill help against PMDD?

Yes, the pill can be helpful for PMDD, but not for all affected individuals and not in every form of use.

When are antidepressants used for PMDD?

Antidepressants are used for PMDS when the psychological symptoms – such as depression, irritability, anger, or anxiety – are severe and other measures (e.g., lifestyle changes, hormone therapy) are not sufficient.

Which herbal remedies help with PMDD?

In the treatment of premenstrual dysphoric disorder (PMDD), many affected individuals look for herbal alternatives to conventional medications.

What can those affected do themselves to relieve their symptoms?

Women with PMDD are not powerless – on the contrary: A conscious approach to their own cycle, targeted lifestyle changes, and supportive measures can significantly help alleviate the symptoms.

Why is PMDS often not recognized or taken seriously?

Despite its clear definition in the international classification systems DSM-5 and ICD-11, premenstrual dysphoric disorder (PMDD) is still often overlooked or trivialized in clinical practice.

Which specialists treat PMDS?

The treatment of premenstrual dysphoric disorder (PMDD) lies professionally at the borderline between gynecology, psychosomatics, and psychiatry.

Is there hope for better care in PMDS?

Yes – the supply situation for women with PMDS is gradually improving, although there is still significant catching up to do in many areas.

What is PMDD and how does it differ from PMS?

Premenstrual dysphoric disorder (PMDD) – also internationally known as Premenstrual Dysphoric Disorder (PMDD) – is a severe, neurobiologically based cycle disorder that causes psychological and partly physical symptoms. It typically occurs in the luteal phase, the second half of the cycle after ovulation, and ends with the onset of menstruation or a few days afterward.

PMDD symptoms

While PMS (premenstrual syndrome) often includes mild to moderate symptoms – such as breast tenderness, mood swings, water retention, or irritability – PMDD is a distinct, medically recognized condition with a clearly defined clinical picture. Since the introduction of DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) and ICD-11 (International Classification of Diseases), PMDD has been classified as a disorder requiring treatment.

Comparison of PMS and PMDD

Feature

PMS – Premenstrual Syndrome

PMDD – Premenstrual Dysphoric Disorder

appearance

Second half of the cycle, a few days before the period

Second half of the cycle, usually from ovulation to the start of menstruation

Frequency

Up to 75% of all menstruating women

About 3–8% of all menstruating women

Symptom profile

Physical and emotional, usually mild to moderate

Primarily psychological, strongly pronounced

Psychological symptoms

Irritability, tearfulness, mood swings

Depression, anger outbursts, suicidal thoughts, loss of control

Daily life impairment

Rather mild to moderate

Significant, often severe impairments in work and private life

Diagnostic status

No clear clinical diagnosis, rather a collective term

Official diagnosis according to DSM-5 and ICD-11

Therapeutic approaches

Lifestyle, nutrition, herbal remedies

Additional psychotherapy, hormone therapy, possibly antidepressants

Summary

PMDD is more than "just" PMS: it is a severe, cycle-dependent affective disorder that is mentally very distressing and often leads to significant impairments in daily life. While PMS is familiar to many women and can usually be managed with non-medical measures, PMDD often requires specialized medical and psychotherapeutic treatment.

How common is premenstrual dysphoric disorder?

Premenstrual dysphoric disorder (PMDD) is a much less frequently diagnosed but clinically significant form of cycle-dependent complaints. It mainly affects women of childbearing age and is considered the most severe form of premenstrual syndrome (PMS). Although the disorder has only recently been more thoroughly studied and diagnostically recorded, reliable epidemiological data now exist.

PMDD causes

Prevalence in numbers

Category

Estimated proportion of affected women

Mild to moderate PMS symptoms

Up to 75% of all menstruating women

Clinically relevant PMS

About 20–30%

Mild form of PMDD

Approx. 5–8%

Severe form of PMDD

About 2–5% (diagnosable according to DSM-5)

Worldwide prevalence (estimated)

Around 3–8% of all menstruating individuals worldwide

These figures are based on a combination of clinical studies, epidemiological surveys, and experience from gynecological and psychosomatic practices. The exact prevalence varies depending on methodology and the definition of diagnostic criteria.

Reasons for the high number of unreported cases

The actual number of affected women could be significantly higher because PMDD is often:

  • is not recognized,

  • is misdiagnosed (e.g., as a depressive episode),

  • or is not reported by those affected – out of shame, ignorance, or because the symptoms are dismissed as "normal."

Especially in countries where ICD-11 has not yet been widely implemented or where menstrual health is taboo, PMDD often remains unrecognized and untreated.

What causes PMDD?

Premenstrual dysphoric disorder (PMDD) is not imagination, not a character weakness, and not purely a psychological reaction to stress. It is a neurobiologically based, cycle-dependent affective disorder whose causes arise from a complex interplay of genetic, hormonal, and neurological factors. While the exact mechanisms are not yet fully understood, modern research provides important insights into its development.

The main causes of PMDD at a glance

Cause/factor

Description

Hormone sensitivity

Oversensitive brain reaction to normal fluctuations of estrogen and progesterone in the second half of the cycle.

Neurotransmitter disorder

Reduced serotonin activity due to increased transporter density before menstruation – leads to depressive symptoms.

Allopregnanolone

Progesterone metabolite negatively affects the GABA-A receptor – in PMDD there is increased neuronal sensitivity.

Genetic predisposition

Studies show a familial clustering. Genetic differences in cellular responses to sex hormones are detectable.

Stress & psychosocial factors

Chronic stress, stressful life situations, or trauma can worsen the symptoms.

Vulnerability after childbirth

Hormonal changes after pregnancies often promote the first occurrence of PMDD.

Neurobiological insights: What happens in the brain?

Recent studies, such as those from the Max Planck Institute Leipzig, show that women with PMDS have an increased density of serotonin transporters in the brain during the second half of the cycle. This results in less serotonin being available at synapses for signal transmission, promoting depressive moods, irritability, and emotional instability.

In addition, the central nervous system of affected women is hypersensitive to allopregnanolone, a neuroactive metabolite of the hormone progesterone that acts via GABA-A receptors. This dysregulation can cause anxiety, loss of control, and irritability – typical PMDS symptoms.

PMDS is not a hormonal disorder – but a disorder of hormone processing

A crucial point: In PMDS, hormone levels (e.g., estrogen, progesterone) are usually within the normal range in laboratory tests. The cause is not a deficiency or excess but an abnormal brain response to these natural fluctuations.

What role does the cycle play in PMDS?

The menstrual cycle phases are the central trigger for the symptoms of premenstrual dysphoric disorder (PMDS). PMDS is strictly cycle-dependent – meaning: the symptoms regularly occur in the second half of the cycle, that is, after ovulation until a few days after the onset of menstruation. After that, they usually subside abruptly until the next cycle begins. This recurring pattern is not only diagnostically indicative but also clearly distinguishes PMDS from other mental illnesses.

Cycle phases and PMDS symptoms

Cycle phase

Hormonal change

Effect on PMDS

Follicular phase

Estrogen rises, progesterone low

Well-being usually stable, symptoms absent

Ovulation

Sudden drop in estrogen

First signs possible: irritability, emotional instability

Luteal phase

Progesterone rises sharply, then falls

Main phase of PMDS symptoms: depression, anger, anxiety

Menstruation

Drop in estrogen & progesterone

Symptoms usually subside or disappear completely

Why does the brain react so sensitively to the cycle?

Women with PMDS do not react to abnormal hormone levels but to normal hormonal fluctuations in an exaggerated way. In particular:

  • Allopregnanolone, a breakdown product of progesterone, paradoxically acts negatively on the GABA-A receptor in sensitive women, promoting anxiety and restlessness.

  • Estrogen influences serotonin metabolism. The drop in estrogen before the period can lead to a functional serotonin deficiency – with depressive consequences.

  • In the luteal phase (approx. day 14–28 of the cycle), this leads to a neurochemical imbalance that triggers PMDS symptoms.

Special feature: Sudden improvement after cycle change

A diagnostic feature of PMDD is the sudden psychological stabilization after the start of menstruation. Many affected describe this as a "clear head," "like waking up," "finally myself again" – which makes the discrepancy between the cycle phases particularly clear.

What symptoms are typical for PMDD?

Premenstrual dysphoric disorder (PMDD) is characterized by a variety of severe, cycle-dependent symptoms – mainly psychological in nature, but also with physical accompanying symptoms. They regularly occur in the second half of the cycle, worsen until shortly before menstruation, and then usually subside abruptly.

Unlike "classic" PMS, where physical complaints such as breast tenderness or water retention are predominant, PMDD is dominated by emotional, affective, and behavioral symptoms that can significantly impair daily life, relationships, and work ability.

Overview of typical PMDD symptoms according to DSM-5

Symptom category

Typical symptoms

Affective symptoms

- Depressive moods

- Feelings of hopelessness

- Self-esteem problems

- Suicidal thoughts

Emotional instability

- Sudden sadness

- Crying without apparent reason

- Hypersensitivity to rejection

Irritability & anger

- Strong irritability

- Aggressiveness

- Outbursts of anger, even towards close persons

Anxiety & tension

- Inner restlessness

- Nervousness

- Excessive fears

Cognitive impairment

- Concentration difficulties

- Feeling mentally overwhelmed

- Disinterest in daily life and hobbies

Physical symptoms

- Breast tenderness/pain

- Headaches

- Muscle/joint pain

- Bloating, weight gain

Behavioral changes

- Social withdrawal

- Loss of control

- Changes in appetite (cravings, overeating)

- Sleep disturbances (insomnia or hypersomnia)

Diagnostic criteria: How many symptoms must be present?

According to DSM-5, for the diagnosis of PMDD:

  • at least 5 symptoms from the above list regularly occur,

  • at least one of which is from the following areas depressive mood, Irritability, anxiety or emotional instability originate,

  • specifically in the week before menstruation, with improvement after the start of bleeding.

These complaints must have been documented in more than two cycles (e.g., through a cycle diary) and lead to a significant impairment of social and professional life.

Special notes

  • The severity of symptoms can vary from cycle to cycle and is often worsened by stress, lack of sleep, or hormonal changes (e.g., after childbirth, after stopping the pill).

  • Those affected often report a feeling of not being themselves – the "Dr. Jekyll & Mr. Hyde" phenomenon is often used as an apt description.

  • In severe cases, there may be emotional loss of control, such as aggressive behavior towards partners or children.

How is PMDS diagnosed?

The diagnosis of premenstrual dysphoric disorder (PMDS) requires care, patience, and systematic observation. Unlike many physical illnesses, PMDS cannot be detected by a blood test or imaging procedures. Instead, the diagnosis is based on a defined symptom catalog and the temporal relationship with the menstrual cycle.

PMDS symptoms

Official diagnostic criteria according to DSM-5

The currently applicable diagnostic criteria come from the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition). These are recognized worldwide as the standard for identifying mental and psychosomatic disorders. In the ICD-11, the international diagnostic classification system valid from 2022, PMDS is also recorded for the first time with its own code.

Criterion

Description

A

At least 5 symptoms must occur during the last week before menstruation and clearly subside within a few days after the start of bleeding.

B

At least one of the symptoms must come from the areas of depressed mood, irritability, anxiety, or mood lability.

C

The symptoms cause significant impairment in social, occupational, or academic areas.

D

The symptoms must not be better explained by another mental disorder (e.g., depression, anxiety disorder).

E

Symptoms must have been documented over at least two menstrual cycles.

The most important tool: The cycle diary

The diagnosis of PMDS cannot be made retrospectively or based on intuition. A cycle diary is absolutely necessary. It documents daily over at least two to three months:

  • Mood
  • Physical symptoms
  • Sleep, energy level, appetite
  • Impact on work, relationships, leisure

Special PMDS cycle diaries are available as PDFs or apps – especially recommended are structured templates from gynecological psychosomatics.

Advantage

Benefit for diagnosis and therapy

Objectivity

Documents cycle-dependent symptom fluctuations

Differentiation

Helps to distinguish PMDS from depression or anxiety disorder

Self-observation

Promotes self-awareness and strengthens self-competence

Therapy monitoring

Evaluates progress under medication or psychological treatment

Differentiation from other disorders

A major diagnostic challenge lies in differentiating from other mental illnesses, especially:

  • Depressions or Dysthymias
  • Anxiety disorders
  • Borderline Personality Disorder
  • Premenstrual Exacerbation (PME) – Worsening of an existing disorder in the luteal phase

Decisive criterion: In PMDS, there is a complete or nearly complete remission of symptoms during the follicular phase (i.e., after menstruation) – whereas in other disorders, symptoms persist.

How does PMDS progress over the years?

Premenstrual dysphoric disorder (PMDS) shows a highly variable individual course closely linked to hormonal changes, life phases, and psychosocial stress. While some women develop initial cycle-dependent symptoms shortly after menarche, manifest PMDS often appears years later – often after significant hormonal changes such as pregnancy, childbirth, stopping the pill, or during perimenopause.

Typical course in the life cycle

Life phase

Possible influence on PMDS course

Adolescence / puberty

First hormonal fluctuations, PMS possible; PMDS rare

20s–30s

Stabilization or first occurrence, e.g., after stopping the pill

After pregnancy / childbirth

More frequent onset or worsening of symptoms due to massive hormonal changes

30s–40s

Most common time for clinically manifest PMDS, often in connection with everyday stress

Perimenopause

Fluctuating symptoms due to unstable hormone levels; often worsening or new onset

Postmenopause

Usually spontaneous improvement or complete disappearance of PMDS

Influencing factors on the course

The course of PMDS is not controlled solely biologically. Psychosocial factors, such as chronic stress, lack of recovery time, excessive responsibility (e.g., due to motherhood and work), lack of self-care, or stressful relationships, also play a role in symptom intensification.

Additionally, individual physical conditions such as:

  • genetic predisposition
  • sensitivity to allopregnanolone
  • imbalances in serotonin levels
  • previous mental illnesses (e.g., depression, trauma)

Prognosis: Chronic condition or temporary disorder?

PMDS is not necessarily a permanent condition. Many women report significant improvement or complete remission:

  • after consistent treatment (e.g., antidepressants, extended-cycle pill, behavioral therapy)
  • due to changes in lifestyle, self-care, and stress management
  • after hormonal changes during menopause

In some cases, however, a flare-up can occur, for example with:

  • high professional or family stress
  • insufficient therapy adherence
  • lack of cycle observation or self-regulation

Cycle management as a long-term strategy

Many affected individuals develop an individual understanding of symptoms and self-management over time, allowing them to consciously influence the course of their PMDS – for example through:

  • Proactive cycle planning
  • Targeted breaks or reduced workload in the luteal phase
  • Intermittent or flexible medication
  • Proven coping strategies (e.g., yoga, mindfulness, therapy)

What treatment options are available for PMDS?

The treatment of premenstrual dysphoric disorder (PMDS) requires an individually tailored, multimodal therapy concept that considers both the neurobiological cause and psychosocial stress factors. The goal is to alleviate the pronounced symptoms in the second half of the cycle and sustainably improve the quality of life of those affected.

Since PMDS is not a classic hormonal disorder in its cause but an abnormal brain response to normal hormonal fluctuations, the treatment differs from conventional PMS therapy.

Overview of treatment options for PMDS

Therapy approach

Method/treatment

Mechanism/goal

Lifestyle optimization

Exercise, nutrition, stress reduction, sleep hygiene, mindfulness

Regulation of hormonal balance, stabilization of the nervous system

Cycle diary & psychoeducation

Documentation & education by doctors or therapists

Promotion of self-awareness and active shaping of one's own cycle

Hormone therapy

Intake of combination preparations (pill) in long-cycle – without breaks

Avoidance of cyclical hormone peaks, stabilization of the neuroendocrine system

SSRIs (antidepressants)

Serotonin reuptake inhibitors such as fluoxetine, sertraline, citalopram (continuous or intermittent)

Improvement of serotonin availability, reduction of depression & irritability

Psychotherapy

Behavioral therapy, possibly combined with relaxation techniques (e.g., PMR, mindfulness training)

Development of emotional regulation, learning coping strategies

Phytotherapy & micronutrients

Chasteberry, turmeric, omega-3 fatty acids, vitamin B6, magnesium

Support of hormonal balance, anti-inflammatory, mood-enhancing

Combination therapy

Pill + SSRI, possibly supplemented by behavioral therapy

Synergistic effect in severe PMDS

SSRIs for PMDS – continuous or intermittent?

A particularly effective therapeutic approach is SSRIs (selective serotonin reuptake inhibitors). They improve serotonin signaling in the brain and thus counteract depressive and affective symptoms. Studies show:

  • continuous administration throughout the entire cycle is especially effective in the acute phase,
  • Upon stabilization, it can be switched to intermittent intake (only luteal phase),
  • The onset of effect often occurs faster than with classic depression – sometimes within a few days.

Active ingredient

Special feature

Fluoxetine

Specifically approved for PMDS in the USA

Sertraline

Good tolerance, often first choice

Citalopram

Low side effect profile

Paroxetine

Highly effective, but possibly more side effects

Escitalopram

Easily controllable, also suitable for interval therapy

When is hormone therapy useful?

Taking hormonal contraceptives in a long cycle, i.e., without a break, can balance cycle-related fluctuations for many women and thus improve PMDS symptoms. The careful selection of the preparation considering:

  • contraindications (e.g., risk of thrombosis)
  • family history
  • age & life phase
  • individual tolerance

Holistic measures & self-help

In addition to medical treatments, many women also benefit from:

  • gentle exercise (e.g., walks, yoga)
  • mindful nutrition (blood sugar stabilizing, anti-inflammatory)
  • targeted self-care (e.g., rest phases in the luteal phase)
  • Relief in everyday life through more conscious cycle planning

Does the pill help against PMDS?

Yes, the pill can be helpful for PMDS, but not for all affected and not in every form of use. Important: The pill helps not because it supplies hormones, but because – when used correctly – it suppresses the natural cycle and thus avoids the hormonal fluctuations responsible for the symptoms of premenstrual dysphoric disorder (PMDS).

Mode of action of the pill in PMDS

In women with PMDS, the brain reacts hypersensitively to hormonal fluctuations, especially to:

  • the rise and fall of progesterone,
  • the metabolite allopregnanolone,
  • and the change in estrogen levels.

By taking hormonal contraceptives – especially combination preparations with estrogen and progestin – the cycle can be artificially stabilized or completely suppressed.

Use in the long cycle: more effective than the classic 21/7 rhythm

To keep hormonal fluctuations as low as possible, a long cycle intake is recommended for PMDS. This means: the pill is taken continuously without breaks, over several months, without a bleeding interval.

Form of administration

Effect on PMDS

Recommendation

21/7 rule (classic)

Hormone drop during the break → symptoms possible

Not recommended for PMDS

Long cycle (e.g., 3–6 months continuously)

No fluctuations, stable hormone levels

Preferred recommendation for PMDS

Continuous cycle (without interruption)

Maximum stability, no withdrawal bleeding

Useful for severe PMDS cases

Study situation & practical experience

  • Clinical studies show that pills containing drospirenone (e.g., with ethinylestradiol + drospirenone) have positive effects on mood and irritability.
  • The pill does not work for all women – especially if the cause is more neurobiologically based.
  • Some women reject hormones or have contraindications (e.g., migraine with aura, increased risk of thrombosis, smoking).

Advantages and limitations of the pill for PMDD

Advantages

Limitations

Hormonal stability

Not all women respond to hormone therapy

Reduction or avoidance of cycle-dependent symptoms

Side effects (e.g., mood crashes, loss of libido) possible

Practical form of administration with long-term effect

Not suitable for those trying to conceive or with certain risk factors

Combination with SSRIs possible

Effectiveness depends on the preparation and individual response

When are antidepressants used for PMDD?

Antidepressants are used for PMDD when psychological symptoms – such as depression, irritability, anger, or anxiety – are severe and other measures (e.g., lifestyle changes, hormone therapy) are insufficient. Mainly SSRIs (selective serotonin reuptake inhibitors) like fluoxetine, sertraline, or citalopram are used.

They can either:

  • Can be taken continuously throughout the entire cycle (especially at the start of treatment), or
  • Intermittently, meaning only in the second half of the cycle, which reduces side effects.

SSRIs often work faster for PMDD than for classic depression – sometimes within a few days. They are considered the first choice for severe PMDD, especially when depressive moods or loss of control dominate.

Which herbal remedies help with PMDD?

​Many affected individuals seek herbal alternatives to conventional medications for treating premenstrual dysphoric disorder (PMDD). Some herbal preparations have proven potentially helpful:​

Chasteberry (Vitex agnus-castus): This herbal remedy is often used to treat menstrual disorders. Studies suggest that chasteberry can particularly relieve breast tenderness and other PMS symptoms. ​

St. John's Wort: Known for its antidepressant effects, St. John's Wort is sometimes used to treat mood swings related to PMS and PMDD. However, it can interact with other medications, so its use should be discussed with a doctor. ​

Evening Primrose Oil: Rich in gamma-linolenic acid, evening primrose oil is used to balance hormonal fluctuations and reduce symptoms such as irritability and breast tenderness. ​

Saffron: Some studies suggest that saffron may have positive effects on depressive moods and premenstrual symptoms. ​

Maca and Ashwagandha: These adaptogenic plants are traditionally used to promote hormonal balance and can support both PMS and PMDS symptoms. ​

PMDS Suppositories

CANNEFF® Suppositories and the Role of CBD

CANNEFF® offers medical products containing cannabidiol (CBD), a non-psychoactive compound from the hemp plant. CBD shows a modulatory effect on the GABA system in studies, which plays a central role in regulating anxiety and stress, especially the extrasynaptic GABAA receptors, also modulated by allopregnanolones. Through positive allosteric modulation of certain GABAA receptors, CBD can produce calming effects that might be helpful for those affected by PMDS. A biologically plausible effective mechanism exists, but clinical evidence is not yet available.

Although many women benefit from herbal preparations, clinical evidence for some of these remedies is limited. Additionally, herbal medicines can interact with other medications or cause side effects. Therefore, it is essential to consult a doctor before taking such preparations to assess individual risks and benefits.

What can those affected do themselves to relieve their symptoms?

Women with PMDS are not powerless – on the contrary: conscious management of their own cycle, targeted lifestyle changes, and supportive measures can significantly help alleviate symptoms. The goal is to reduce emotional strain in the second half of the cycle, strengthen resilience, and better manage daily life. While self-help does not replace medical treatment for severe PMDS, it can be an important complement.

Overview: Self-Help Strategies for PMDS

Area

Recommended Measures

Cycle Awareness

Keeping a cycle diary to recognize patterns and better plan symptoms

Stress reduction

Mindfulness training, meditation, breathing exercises, progressive muscle relaxation

Exercise

Moderate exercise (e.g., yoga, walks, swimming) – reduces cortisol, stabilizes mood

Nutrition

Blood sugar-stable diet, omega-3 fatty acids, little sugar, alcohol, caffeine, and highly processed foods

Plant Power

Vitex, turmeric, saffron, magnesium, vitamin B6 – targeted and after consulting professionals

Social Self-Care

Withdrawal when necessary – but no social isolation; open conversations with partners and family

Everyday Structure

Avoid scheduling critical appointments during the luteal phase if possible; plan buffers

Resource Care

Activities that feel good – music, creative hobbies, nature, journaling, wellness rituals

Cycle-based lifestyle design

A particularly effective self-help approach is the so-called cycle-based time management. This involves consciously scheduling work-intensive phases in the first half of the cycle, while the second half is deliberately used for regeneration and reflection. This can help avoid emotional overload and regain a sense of control.

CBD suppositories as a supportive measure

As mentioned in the previous section, CANNEFF® vaginal suppositories with CBD and hyaluronic acid can also be used supportively – especially in the second half of the cycle. CBD modulates the GABAA system, which plays a central role in PMDD, and can have a calming and balancing effect. This plant-based medicinal supplement is available without a prescription but should ideally be part of a holistic strategy. Clinical studies have shown that in menopausal women, CANNEFF CBD suppositories can improve physiological menopause symptoms such as inner restlessness, sleep disorders, or hot flashes and enhance women's quality of life.

Why is PMDD often not recognized or taken seriously?

Despite its clear definition in the international classification systems DSM-5 and ICD-11, premenstrual dysphoric disorder (PMDD) is still often overlooked or trivialized in clinical practice. The reasons for this are varied – ranging from insufficient professional training to societal taboos and medical misperception of cycle-dependent symptoms.

Reasons for the lack of recognition of PMDD

Cause

Impact on diagnosis and treatment

Insufficient medical training

PMDD is often only briefly covered in medical studies and gynecological specialist training.

Outdated diagnostic systems

In ICD-10, there was no separate PMDD diagnosis – this was only corrected with ICD-11.

Tabooing of menstruation

Menstruation-related complaints are often considered “normal” and trivialized.

Misdiagnoses

PMDD is often mistakenly classified as depression, anxiety disorder, or personality disorder.

Nonspecific symptoms

Many symptoms (e.g., irritability, fatigue, concentration problems) initially appear nonspecific.

Cycle connection not recognized

Without a cycle diary, the timing connection between symptoms and menstruation remains unclear.

Stigmatization of emotional women

Emotional fluctuations are dismissed as exaggerated or “hysterical” – especially in women.

Social and psychological aspects

  • “That's just how it is with women” – many affected hear this phrase from doctors, partners, or colleagues. This attitude leads to complaints not being taken seriously but rather pathologized or ignored.
  • Many women are ashamed to talk about their symptoms – especially when they involve intense anger, suicidal thoughts, or aggression.
  • As a result, a feeling of isolation and self-doubt develops – even though the cause is biologically based and medically recognized.

Consequences of delayed diagnosis

A long suffering process is typical for many women with PMDD. Often several specialists are consulted before the correct diagnosis is made. During this time:

  • relationships and work performance deteriorate,
  • secondary psychological burdens arise, such as fear of losing control or depressive episodes,
  • trust in medical help and in one's own body decreases.

Which specialists treat PMDD?

The treatment of premenstrual dysphoric disorder (PMDD) lies professionally at the intersection of gynecology, psychosomatics, and psychiatry. Therefore, it is understandable that many affected individuals are unsure whom to turn to. The right point of contact often depends on the severity of symptoms, previous treatment history, and individual life situation.

Specialty

Responsibility and role in PMDD

Gynecologist

First contact: cycle diagnostics, hormonal treatment (e.g., extended-cycle pill), prescription of herbal preparations

Specialist in psychiatry

Assessment and prescription of antidepressants (SSRIs) for severe psychological symptoms

Psychotherapist (CBT/Psychodynamic)

Support with emotional regulation, self-management, stress processing

Psychosomatic medicine

Combination of psychotherapeutic and medical approach – especially suitable for PMDD

General practitioner

Entry into care, issuing referrals, basic counseling

Why gynecologists often (still) hesitate

Although PMDD is clearly linked to the menstrual cycle, many gynecologists feel uncertain about treatment, especially regarding psychological symptoms or prescribing SSRIs. Reasons for this include:

  • lack of training in dealing with affective disorders,
  • uncertainty in handling psychopharmacological therapy options,
  • outdated diagnostic systems (ICD-10 did not include PMDD as an independent diagnosis).

Interdisciplinary care as the ideal

In severe cases, interdisciplinary collaboration is ideal – for example, between gynecologists, psychotherapists, and psychiatrists. This allows for holistic care that considers hormonal, emotional, and social dimensions.

Specialized centers, such as those for psychosomatic gynecology or women's mental health (e.g., in university hospitals), often offer integrated care for PMDD.

Is there hope for better care for PMDD?

Yes – the care situation for women with PMDD is gradually improving, even though there is still significant catch-up needed in many areas. Thanks to medical advances, new classifications, and growing public awareness, premenstrual dysphoric disorder is increasingly recognized as a real, treatable condition – not only by professionals but also socially.

Three key advances in PMDD care

Development

Significance for care

Introduction of PMDD into ICD-11

Since 2022, PMDD has been independently classified in the international diagnostic catalog → better coding & billing options

Increase in research and education

New studies on neurobiology, hormone receptors, and therapy options → more expertise and targeted treatments

Growing public attention

Media, books, and online platforms address PMDD → breaking the taboo and more self-help options

Beacons of hope in diagnosis and therapy

  • Cycle diaries and specialized apps now help to accurately record symptoms – the basis for a correct diagnosis.
  • New SSRI strategies (e.g., intermittent use) enable individually tailored therapies with fewer side effects.
  • Increasing gynecological psychosomatics in clinics improves interdisciplinary care.
  • Inclusion in guidelines and training programs for doctors promotes understanding of cycle-dependent affective disorders.

Challenges remain – but awareness is growing

Despite these advances, PMDD is:

  • still too rarely correctly diagnosed,
  • often mistaken for depression or burnout,
  • and perceived by some professionals as "exaggerated."

But that is changing. More and more women are openly sharing their experiences. 

Back to the blog
Philip Schmiedhofer, MSc

Philip Schmiedhofer, MSc

Medical Technician & Neuroscientist

Philip is the managing director and co-founder of cannmedic GmbH. With a degree in medical engineering and molecular biology, specializing in neuroscience and focusing on cannabinoids, he is recognized as an expert in the application of cannabinoids in medicine. As a medical device consultant, he leads the sales of cannmedic and offers specialized advice to medical professionals. His expertise includes the development and sales of cannabinoid-based products. In the field of research, he participates in significant basic research at the Center for Brain Research at the Medical University of Vienna. As co-founder and current managing director of cannhelp GmbH, a pioneer in the CBD sector, he has many years of entrepreneurial experience. Furthermore, he maintains an extensive network in the industry and advises internationally operating companies in the field of medical cannabinoids.